India sees a significant rise in overweight and obese populations recently. Rural areas show a particularly sharp increase in these health ...

Sun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...

Dermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen efflu...

Demand for nutrition professionals is rapidly rising across India. Hospitals and digital health platforms are hiring more dietitians and ed...

Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...

Torrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman...

Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...

Markets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quart...

Cipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...

Dr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year...

Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and pla...

The healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disea...

South Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement die...

Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the ...

Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...

Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...